Cobenfy Trial Showed Cognitive Benefits

The drug xanomeline-trospium demonstrated improved cognition for schizophrenia patients in phase 3 clinical trials.

Updated on Sept. 28, 2026 in Alzheimer’s

Close-up of a laboratory beaker with a clear solution on a sterile surface, representing medical research. — The schizophrenia drug Cobenfy, known as xanomeline-trospium, showed improved cognitive outcomes for patients during successful Phase 3 clinical trials. AI Illustration. Upload story photo >

Live Poll

Are you optimistic that new schizophrenia treatments will improve long-term outcomes for patients?

The schizophrenia drug Cobenfy, known as xanomeline-trospium, has shown cognitive benefits in patients during phase 3 clinical trials. The medication effectively targets muscarinic receptors to treat symptoms without relying on traditional dopamine or serotonin pathways.

Why it matters

Unlike traditional antipsychotics, this treatment avoids common side effects like weight gain and metabolic syndrome by bypassing D2 dopamine receptors. This shift in mechanism offers a new therapeutic pathway for managing schizophrenia without the negative impact on metabolism.

Researchers observed cognitive improvements in patients who scored at least 1 standard deviation below the population mean during phase 3 testing. This assessment utilized prospective testing batteries to measure cognitive outcomes across participants.

The players

Eli Lilly

This global pharmaceutical corporation originally developed the compound xanomeline for use in treating Alzheimer disease.

Cobenfy

This is the brand name for the pharmaceutical drug xanomeline-trospium, a muscarinic receptor agonist used to treat schizophrenia.

The details

Cobenfy functions as a muscarinic receptor agonist, distinct from conventional treatments that block D2 receptors and often trigger extrapyramidal symptoms or prolactin elevation. Originally developed by Eli Lilly for Alzheimer disease, the drug has now demonstrated effectiveness in addressing cognitive impairment associated with schizophrenia.

A phase 2 post hoc cognitive analysis was published in 2022.
The EMERGENT-2 phase 3 trial results were published in 2024.

Health Landscape

The clinical findings follow a pattern established by the EMERGENT-2 phase 3 trial by validating the efficacy of targeting muscarinic receptors. This approach represents a broader transition in psychiatry toward novel mechanisms that avoid the traditional side effects of dopamine-blocking antipsychotics.

Patients may find that this treatment offers a new option that avoids weight gain and metabolic syndrome side effects common in older medications. It allows for potential management of schizophrenia symptoms without the physical burdens often associated with D2 receptor blockers.

The takeaway

The development of muscarinic receptor agonists highlights a successful pivot of compounds originally intended for Alzheimer disease toward new psychiatric applications. Future treatments may continue to refine these mechanisms to further reduce side effects while improving patient cognitive function.